
AN2 Therapeutics rose 366.1% from $1.09 to $5.08, ahead of the S&P 500's +4.7%. Its worst day was Oct 13 (−16.3%), and its low came Feb 18 at $1.03.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
AN2 Therapeutics closed at its lowest level of the year, 5.5% below where the year started.
−1.9% · S&P 500 +0.5%
AN2 Therapeutics shares rose 84.2%, while the S&P 500 rose 0.9%.
Story events cover the past 12 months · Times ET
+84.2%, the year's best day, on 58M shares, the year's heaviest volume · S&P 500 +0.9%
EPS of $-0.29 missed the $-0.24 estimate on $0.00 revenue.
−7.6% · S&P 500 −1.4%
EPS of $-0.29 missed the $-0.23 estimate on $0.00 revenue.
−9.5% · S&P 500 −0.2%
EPS of $-0.18 beat the $-0.24 estimate on $0.00 revenue.
+7.0% · S&P 500 +0.3%
EPS of $-0.17 beat the $-0.20 estimate on $0.00 revenue.
0.0% · S&P 500 +2.4%
Where it ended: a close of $5.08 on Nov 20, 2026. Up next: Q4 2026 earnings on Mar 16, 2027 (EPS est. $-0.20).
Nothing in the past 12 months.
All ANTX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ANTX and SPY from Benzinga historical bars. Not investment advice.